Claims for Patent: 7,838,504

Summary for Patent: 7,838,504

Title:	Methods and compositions for reducing viral genome amounts in a target cell
Abstract:	Methods and compositions for reducing viral genome amounts in a target cell are provided. In the subject methods, the activity of a miRNA is inhibited in a manner sufficient to reduce the amount of viral genome in the target cell, e.g., by introducing a miRNA inhibitory agent in the target cell. Also provided are pharmaceutical compositions, kits and systems for use in practicing the subject methods. The subject invention finds use in a variety of applications, including the treatment of subjects suffering from a viral mediated disease condition, e.g., an HCV mediated disease condition.
Inventor(s):	Sarnow; Peter (Palo Alto, CA), Jopling; Catherine L. (Beeston, GB), Lancaster; Alissa M. (Portland, OR)
Assignee:	The Board of Trustees of the Leland Standford Junior University (Palo Alto, CA)
Application Number:	11/953,705
Patent Claims:	1. A method of reducing viral genome amount comprising contacting a cell infected with Hepatitis C virus with an antisense oligonucleotide complementary to miR-122, and at least one additional agent selected from the group consisting of an antiviral agent and an interferon. 2. The method of claim 1, wherein the at least one additional agent is an antiviral agent. 3. The method of claim 1, wherein the at least one additional agent is an interferon. 4. The method of claim 3, wherein the interferon is interferon alfa-2b. 5. The method of claim 3, wherein the interferon is interferon alfa-2a. 6. The method of claim 3, wherein the interferon is interferon alfacon-1. 7. The method of claim 3, wherein the interferon is a pegylated interferon. 8. The method of claim 1, wherein the cell is in vivo. 9. The method of claim 1, wherein the cell is in vitro. 10. The method of claim 1, wherein said method comprises administering the antisense oligonucleotide and the at least one additional agent to a subject comprising the cell infected with Hepatitis C virus. 11. The method of claim 1, wherein miR-122 has the nucleobase sequence of SEQ ID NO: 20. 12. The method of claim 1, wherein the antisense oligonucleotide is completely complementary to miR-122. 13. The method of claim 1, wherein the antisense oligonucleotide comprises a nucleotide sequence of SEQ ID NO:18. 14. The method of claim 1, wherein the antisense oligonucleotide comprises a nucleotide sequence of SEQ ID NO:15. 15. The method of claim 1, wherein said antisense oligonucleotide complementary to miR-122 comprises a 2'-O-methyl modification. 16. The method of claim 2, wherein the antiviral agent is ribavirin.

Details for Patent 7,838,504

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2024-05-04
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2024-05-04
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2024-05-04